0001140361-22-023308.txt : 20220616 0001140361-22-023308.hdr.sgml : 20220616 20220616203229 ACCESSION NUMBER: 0001140361-22-023308 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220616 FILED AS OF DATE: 20220616 DATE AS OF CHANGE: 20220616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHWARTZ BRIAN CENTRAL INDEX KEY: 0001431322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 221022096 MAIL ADDRESS: STREET 1: C/O ARQULE, INC. STREET 2: 1 WALL STREET, 6TH FLOOR CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 form4.xml FORM 4 X0306 4 2022-06-16 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001431322 SCHWARTZ BRIAN C/O INFINITY PHARMACEUTICALS, INC. 1100 MASSACHUSETTS AVENUE, FLOOR 4 CAMBRIDGE MA 02138 true Common Stock 2022-06-16 4 A 0 30919 0.679 A 30919 D Stock Option(right to buy) 0.679 2022-06-16 4 A 0 45000 0 A 2032-06-16 Common Stock 45000 45000 D Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 50% of such person's $42,000 annual retainer for service as a director. The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Exhibit 24 - Limited Power of Attorney /s/Seth A. Tasker as attorney-in-fact for Brian Schwartz, M.D. 2022-06-16 EX-24 2 brhc10038853_ex24.htm EXHIBIT 24

Exhibit 24

LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
 
Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Adelene Q. Perkins, Lawrence E. Bloch, and Seth A. Tasker, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power of authority as hereinafter described to:
 
1.          execute for and on behalf of the undersigned, in the undersigned capacity as an officer and/or director of Infinity Pharmaceuticals, Inc. (the “Company”), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the “Exchange Act”);
 
2.          do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4 or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority;
 
3.          seek or obtain, as the undersigned representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
 
4.          take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
 
The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company  assuming nor relieving, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.  The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.
 
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
 
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 7, 2021.
 
 
Signature
 
/s/ Brian Schwartz
 
   
 
Print Name
 
Brian Schwartz